but competition has intensified and the firm and the company is short on new product launches.research and development of new drugs is continuing apace, with r d spending rising 37% to 705m rupees a key cause of the decrease in profits alongside the fall in sales.patents on a number of well known products are due to run out in the near future, representing an opportunity for dr reddy, whose shares are listed in new york, and other indian generics manufacturers.sales in dr reddy's generics business fell 8.6% to 966m rupees.